Danish Medicines Council recommends Genmab-developed sclerosis drug
On Thursday, the Danish Medicines Council announced that sclerosis drug Kesimpta, which is owned by Novartis but was developed by Genmab, can be used to treat Danes with relapsing remitting multiple sclerosis and high disease activity.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen and catherine brett
In December, the Danish Medicines Council wasn’t convinced of the therapeutic advantages of Novartis’s sclerosis drug, Kesimpta.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab: Darzalex sales in line with expectations
For subscribers
Analyst: Novartis's Kesimpta sales exceeded expectations
For subscribers
